Ultime notizie per Ocean Biomedical (NASDAQ:OCEA) Azioni

Ocean Biomedical

Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.

Ocean Biomedical Inc

Ocean Protocol - United States Dollar

OCEAN WILSONS ORD

OCEANEERING INTERNATIONAL ORD

Ocean Capital Acquisition Corp

Ocean Capital Acquisition Corporation

Ocean Drive Acquisition Corp

Ocean Park High Income ETF

Ocean Park International ETF

Ocean Power Technologies, Inc. Common Stock

Ocean Power Technologies Inc

OCEAN SPRAY 4 PR by Ocean Spray Cranberries, Inc.

Ocean Spray Cranberries Inc

OCEAN THERMAL ENERGY CORP by Ocean Thermal Energy Corp.

Ocean Thermal Energy Corp

OceanFirst Financial Corp. - Common Stock

OceanFirst Financial Corp

OceanFirst Financial Corp. - Depositary Shares

OceanPal Inc

OceanTech Acquisitions I Corp Units (1 Ord Class A & 1 War)

OceanTech Acquisitions I Corp

OceanTech Acquisitions I Corp Warrants (12/05/2026)

OceanTech Acquisitions I Corp Class A

Oceana Group Ltd

OceanaGold Corp

OCEANAGOLD (PHILIPPINES) by OCEANAGOLD (PHILIPPINES) INC.

OceanaGold Philippines Inc

Oceaneering International, Inc. Common Stock

Oceaneering International Inc

OCEANIA HEALTHCARE LTD by Oceania Healthcare Ltd.

Oceania Healthcare Ltd

OCEANIC IRON ORE CORP NEW by Oceanic Iron Ore Corp.

Oceanic Iron Ore Corp

OCEANIC WIND ENERGY INC. by Oceanic Wind Energy Inc.

Oceanic Wind Energy Inc

OCEANSIX FUTURE PATHS LTD by OCEANSIX FUTURE PATHS LTD.

Oceansix Future Paths Ltd

RBC Capital analyst Jimmy Shan maintains InterRent REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IIP#TSX">IIP</a>) with a Outperform and lowers the price target from C$16.5 to C$15.

News

Price Target

Analyst Ratings

TSX:IIP

TSX:IIP/UN

RBC Capital Maintains Outperform on InterRent REIT, Lowers Price Target to C$15

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;reported third-quarter sales of $95.43 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $92.75 billion</a>.&nbsp;
Total revenues increased 6.3%, primarily driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769047/cvs-health-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">Health Services segment</a>.
Adjusted EPS of $1.09 (inline with preliminary guidance of $1.05-$1.10) decreased from $2.21 in the prior year, missing the consensus of $1.53. The fall was primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflects continued utilization pressure and premium deficiency reserves of approximately $1.1 billion, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual <a target="_blank" href="https://www.benzinga.com/news/24/11/41719665/cvs-health-q3-earnings-preview-can-the-company-overcome-recent-challenges" rel="noreferrer noopener">exchange product lines</a>.
Adjusted operating income decreased 77.5% to $2.55 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
During the third quarter of 2024, CVS Health <a target="_blank" href="https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2024/Q3-2024-Earnings-Release.pdf" rel="noreferrer noopener">finalized</a> its restructuring plan and recorded restructuring charges of approximately $1.2 billion, including store impairment charges for additional retail pharmacy stores it plans to close in 2025.
Revenues in the Health Care Benefits segment increased 25.5% to $32.99 billion. The Medical benefit ratio increased to 95.2% from 85.7% a year ago. Medical membership reached 27.1 million.
Health Services segment revenues decreased 5.9% to $44.13 billion. Pharmacy claims processed decreased 16.5%.
Concurrently, CVS&nbsp;Health announced&nbsp;that Prem&nbsp;Shah will be Group President and responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna. Both appointments are effective today.
Pharmacy &amp; Consumer Wellness segment revenues increased 12.3% to $32.42 billion, primarily driven by increased prescription volume, including increased contributions from vaccinations and pharmacy drug mix.
In October, CVS Health appointed David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
The company also withdrew the 2024 guidance provided in the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">second-quarter earnings release</a>.
Price Action:&nbsp;CVS stock is up 11.30% at $61.60&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41754167/why-is-astrazeneca-stock-sinking-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is AstraZeneca Stock Sinking On Tuesday?</a></li>
</ul>
Image via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

General

CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit

RBC Capital analyst Irene Nattel maintains Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) with a Outperform and raises the price target from C$34 to C$35.

TSX:PET

RBC Capital Maintains Outperform on Pet Valu Hldgs, Raises Price Target to C$35

WIIM

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading higher after Donald Trump was elected president of the United States, which could raise concerns over potential tariffs and US-China tensions.

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $195 to $205.

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $205

Warren Buffett, one of the world&#8217;s most successful investors, has shared plenty of advice over his long career. But one <a href="https://www.benzinga.com/news/23/07/33245523/warren-buffetts-no-1-investing-rule-dont-lose-money-practical-advice-for-a-billionaire-but-can-regul">piece of advice</a> stands out as his top rule: &#8220;The first rule of investment is don&#8217;t lose money.&#8221; And if you ask about the second rule? &#8220;Don&#8217;t forget the first.&#8221; According to Buffett, that&#8217;s all you need to know.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">1. Warren Buffett "Rule no.1 is don't lose and the second rule is never forget rule 1." &#x1f410; <a href="https://t.co/x0hEOgxVJ4">pic.twitter.com/x0hEOgxVJ4</a>
&mdash; Oliver &#x7C; MMMT Wealth (CPA) (@MMMTwealth) <a href="https://twitter.com/MMMTwealth/status/1850983304167571542?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
It might sound simple — even a bit obvious. After all, who wants to lose money? But Buffett's point is more profound than it might first appear. <a href="https://www.benzinga.com/news/24/09/41091380/warren-buffet-tells-investors-to-give-up-on-me-vs-stock-approach-what-tells-you-whether-you-should-k">His investment philosophy</a> is about protecting what you already have. If you lose a big chunk of your investment, you need a huge return just to get back to where you started.&nbsp;
For example, when a stock drops by a big margin, it requires an even greater gain just to get back to its original value. It's much easier to prevent these kinds of losses in the first place than to claw your way back from them.&nbsp;
Of course, saying &#8220;don't lose money&#8221; is easier than actually following through, especially with the ups and downs of the stock market. But there are practical strategies investors can use to help follow Buffett&#8217;s rule.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
You lower the chance of suffering a significant loss on any one investment by <a href="https://www.benzinga.com/money/how-to-diversify-your-portfolio">distributing your funds over several stocks or sectors</a>. Your portfolio can still be balanced even if one or two stocks do not perform well.
Buffett is known for investing in businesses with <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">strong fundamentals</a> that he believes will be successful for many years to come. He prefers companies with a competitive edge, solid management, and products people will continue to buy. Instead of chasing the cheapest stocks, he looks for good companies at reasonable prices.
The market can be a rollercoaster, and emotions like fear or greed often cause people to make costly mistakes. Buffett's approach is to stay calm when others are panicking and to make decisions based on logic, not emotion.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
It's worth noting that even Warren Buffett has lost money, and he has been open about what he thinks are his biggest investment mistakes. He has also stated that one of his worst missteps was purchasing Berkshire Hathaway, a textile company that was initially in decline. Nevertheless, Buffett has been successful over the long term despite these setbacks because he is focused on limiting losses and learning from his mistakes.
<h2 class="wp-block-heading">Alternative Opinions</h2>
On the other hand, some investors think that taking measured risks, even at the expense of occasional losses, is a necessary component of attaining sizable returns, even if Buffett&#8217;s advice to avoid losses is generally accepted. <a href="https://www.benzinga.com/personal-finance/24/06/39360926/diversification-thats-for-idiots-mark-cuban-slams-warren-buffetts-investment-strategy-i-think-bu">Mark Cuban, for example, once said</a>, &#8220;Diversification, that&#8217;s for idiots&#8221; and that &#8220;buy and hold is a crock of s&#x2A;&#x2A;&#x2A;.&#8221;
Plus, startups, emerging technologies, and high-growth companies often come with higher risk but also the potential for substantial gains — something that Buffett's cautious approach might miss.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

'The First Rule Of Investment Is Don't Lose,' Says Warren Buffett. The Second Rule? Don't Forget The First — 'That's All The Rules'

In the current session, SBA Comms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is trading at $218.54, after a 4.30% drop. Over the past month, the stock fell by 7.45%, and in the past year, by 0.22%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_0.png" alt="Past Year Chart" />

<h3>A Look at SBA Comms P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
SBA Comms has a lower P/E than the aggregate P/E of 52.76 of the Specialized REITs industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730906184_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

SBAC

P/E Ratio Insights for SBA Comms

BITF

CLSK

COIN

HIVE

MARA

RIOT

Shares of crypto-linked stocks are trading higher amid strength in Bitcoin, which reached an all-time high during the US presidential election.

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and raises the price target from $395 to $400.

Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $400

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $43 to $30.

APLS

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $30

RBC Capital analyst Pammi Bir maintains BTB Real Estate Investment Trust (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTB#TSX">BTB</a>) with a Sector Perform and raises the price target from C$3.5 to C$3.75.

TSX:BTB

RBC Capital Maintains Sector Perform on BTB Real Estate Investment Trust, Raises Price Target to C$3.75

Wells Fargo analyst Elyse Greenspan maintains American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) with a Equal-Weight and lowers the price target from $77 to $76.

Wells Fargo Maintains Equal-Weight on American Intl Gr, Lowers Price Target to $76

On Tuesday, Exact Sciences Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of $0.20.</a>
The reported quarterly sales of $708.66 million missed the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" rel="noreferrer noopener">estimate of $717.66 million</a>.
Screening revenue was $545 million, an increase of 15%, and Precision Oncology&#8217;s revenue was $164 million, an increase of 5% on a reported and core revenue basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>.
&#8220;While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; said Kevin Conroy, chairman and CEO.
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million &#8211; $675 million.
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
While these explanations are logical, they raise questions about why certain factors weren&#8217;t identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company&#8217;s control.
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41753865/apollos-fee-related-earnings-growth-sets-it-apart-in-alternative-assets-says-goldma" target="_blank" rel="noreferrer noopener">Apollo&#8217;s Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast</a></li>
</ul>

Analyst Color

Trading Ideas

EXAS

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) shares <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">are trading lower on Wednesday.</a>
The company reported third-quarter adjusted earnings per share of 71 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769448/the-odp-corporation-announces-third-quarter-2024-results" rel="noreferrer noopener">missing the street view of $1.60.</a>
Quarterly sales of $1.780 billion, down 11% year-over-year, missed the analyst consensus of $1.820 billion.
The decrease in reported sales is largely related to lower sales in its Office Depot Division, primarily due to 53 fewer retail locations in service compared to the previous year and reduced transactions, as well as lower sales in its ODP Business Solutions Division.
&#8220;We&#8217;re leveraging our differentiated core strengths to pivot towards higher growth B2B opportunities, and we are beginning to see promising traction at both our ODP Business Solutions and Veyer Divisions,&#8221; said Gerry Smith, chief executive officer.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft" rel="noreferrer noopener">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a>
In the quarter under review, adjusted EBITDA was $62 million, compared to $138 million in the year-ago period.
As of September 28, ODP had total available liquidity of approximately $728 million, consisting of $192 million in cash and equivalents.
In a separate press release, the company announced a partnership with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41769797/the-odp-corporation-embarks-on-a-new-10-year-1-5b-transformative-partnership-with-nationally-recog" rel="noreferrer noopener">nationally recognized strategic reseller</a>. This partnership, worth up to $1.5 billion spanning a 10-year period, will leverage the reseller provider&#8217;s expertise in creating custom, results-driven e-commerce solutions and the company&#8217;s extensive fulfillment centers and delivery network.
Outlook: ODP has <a target="_blank" href="https://www.theodpcorp.com/news-releases/news-release-details/odp-corporation-announces-second-quarter-2024-results" rel="noreferrer noopener">lowered </a>its full-year 2024 adjusted EPS guidance from a range of $4.25 &#8211; $5.00 to $3.10 &#8211; $3.80, below the $4.27 analyst estimate.
The company expects sales to be approximately $7 billion (prior view: at least $7 billion), compared to the $7.09 billion estimate.
Price Action: ODP shares are trading lower by 15.2% to $26.37 at last check Wednesday.
Photo via <a href="https://commons.wikimedia.org/wiki/File:Office_Depot_%284190699897%29.jpg">Wikimedia Commons</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy" target="_blank" rel="noreferrer noopener">Trump&#8217;s Historic Return: 7 Ways His Second Term Could Impact The US Economy</a></li>
</ul>

Equities

Office Depot's Parent Company ODP Slashes 2024 Outlook After Weak Q3 Earnings, Eyes B2B Pivot To Offset Retail Woes

Wells Fargo analyst Michael Brown maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $149 to $164.

Wells Fargo Maintains Overweight on Apollo Global Management, Raises Price Target to $164

CRON

SNDL

TLRY

Shares of cannabis stocks are trading lower after a cannabis legalization initiative did not pass in Florida.

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).
On Tuesday, Broadcom expanded its multi-year partnership with Telia Company to advance Telia's modernization and transformation of telecom and cloud infrastructure using <a href="https://www.benzinga.com/markets/equities/24/11/41739196/broadcom-powers-telias-modernization-with-vmware-launches-ai-driven-velorain-more">VMware's product portfolio</a>.
SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) is a &#8220;very complicated story&#8221; as the company is losing a lot of money, Cramer said.
SkyWater Technology will report its fiscal third-quarter financial results following the close of the market on Thursday, Nov. 7.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is a &#8220;really good&#8221; company, Cramer said. &#8220;I think you got a great stock there.&#8221;
On Sept. 26, IES Holdings announced the appointment of John Louis Fouts to its Board of Directors.
S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is a buy, the &#8220;Mad Money&#8221; host said.
On Nov. 1, S&amp;P Global said it has completed the sale of its PrimeOne business to TS Imagine, a global, cross-asset provider of trading, portfolio, and risk management solutions for financial institutions.
Cramer recommended to buy more of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shares.
On Oct. 31, Merck reported third-quarter sales of $16.66 billion, up 4% year over year and beating the consensus estimate of $16.47 billion.
Price Action:
<ul>
<li>Broadcom shares gained 3.2% to settle at $173.90 on Tuesday.</li>
<li>SkyWater Technology shares fell 0.3% to close at $9.65 on Tuesday.</li>
<li>IES Holdings shares gained 3.3% to settle at $246.06 during the session.</li>
<li>S&amp;P Global gained 0.8% to settle at $489.71 on Tuesday.</li>
<li>Merck shares fell 0.2% to close at $101.65.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

AVGO

IESC

SKYT

SPGI

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom

RBC Capital analyst Sabahat Khan maintains Boyd Group Services (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BYD#TSX">BYD</a>) with a Outperform and lowers the price target from C$280 to C$277.

TSX:BYD

RBC Capital Maintains Outperform on Boyd Group Services, Lowers Price Target to C$277

Wells Fargo analyst Neil Kalton maintains Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Equal-Weight and raises the price target from C$59 to C$63.

TSX:FTS

Wells Fargo Maintains Equal-Weight on Fortis, Raises Price Target to C$63

SPDR Dow Jones Industrial Average ETF Trust

Manjor indexes are higher after Donald Trump was elected president of the United States.

At least that is what the poet T.S. Eliot wrote in the opening line of his well-known poem, "The Wasteland". With all the chatter about an April correction it might be, but traditionally April is one of the strongest months for the stock market.

Tuesday Talk: April Is The Cruelest Month?

The latest update is out from Ocean Biomedical (OCEA). Ocean Biomedical, Inc. has delayed its annual financial report and received a notice from Na...

Ocean Biomedical Faces Compliance Challenges and Delays Report

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ocean Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocea-stock-quote/">OCEA</a>) just reported results for the third quarter of 2023.<ul><li>Ocean Biomedical reported earnings per share of -53 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ocea-stock-earnings-ocean-biomedical-for-q3-of-2023/">OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023

Ocean Biomedical gets non-compliance notice from Nasdaq

An update from Ocean Biomedical (OCEA) is now available. Ocean Biomedical, Inc. has delayed its quarterly report filing, leading to a notice from N...

Ocean Biomedical Faces Nasdaq Non-Compliance Notice and Delays

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Wednesday morning!



Moving stocks this morning are delisting notices, an acquisition plan, a public share offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Sify Technologies Limited &ndash; Rights (NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) are rocketing more than 49% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">ahead of their delisting next week</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) stock is soaring over 47% with heavy pre-market trading.</li>



<li>Wang &amp; Lee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlgs-stock-quote/">WLGS</a>) shares are surging close to 40% with strong early morning trading.</li>



<li>Singing Machine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mics-stock-quote/">MICS</a>) stock is gaining more than 29% <a href="https://www.nasdaq.com/press-release/singing-machine-acquire-semicab-leading-ai-logistics-technology-company-2024-06-12">on acquisition news</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are increasing nearly 25% this morning.</li>



<li>Beamr Imaging (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmr-stock-quote/">BMR</a>) stock is rising over 23% after <a href="https://seekingalpha.com/news/4115034-beamr-imaging-product-now-on-oracle-cloud-marketplace-shares-jump-30?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">adding its product</a> to a new marketplace.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) shares are climbing more than 16% as they continue to rise on <a href="https://www.nasdaq.com/press-release/molecular-partners-and-orano-med-share-positive-preclinical-data-their-dll3-0">positive preclinical data</a>.</li>



<li>Surf Air Mobility (NYSE:<a href="https://investorplace.com/stock-quotes/srfm-stock-quote/">SRFM</a>) stock is jumping over 15% on Wednesday morning.</li>



<li>Ocean Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocea-stock-quote/">OCEA</a>) shares are heading 15% higher this morning.</li>



<li>NovaBay Pharmaceuticals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nby-stock-quote/">NBY</a>) stock is up more than 12% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>ThermoGenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/thmo-stock-quote/">THMO</a>) stock is plummeting over 41% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318387950&amp;type=PDF&amp;symbol=THMO&amp;cdn=c35080a0c43a3214912906647bd85f4c&amp;companyName=ThermoGenesis+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-11">on a delisting notice</a>.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving almost 32% on a <a href="https://www.nasdaq.com/press-release/tonix-pharmaceuticals-announces-proposed-public-offering-2024-06-11">proposed public offering</a>.</li>



<li>U-BX Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ubxg-stock-quote/">UBXG</a>) stock is tumbling more than 26% after rallying yesterday.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are taking an over 24% beating on Wednesday morning.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is sliding more than 22% <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">after rallying yesterday</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are retreating over 19% <a href="https://investorplace.com/2024/06/why-is-nauticus-robotics-kitt-stock-up-59-today/">after yesterday&rsquo;s rally</a>.</li>



<li>Blue World Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/bwaq-stock-quote/">BWAQ</a>) stock is falling more than 17% after rising higher yesterday.</li>



<li>Chanson International (NASDAQ:<a href="https://investorplace.com/stock-quotes/chsn-stock-quote/">CHSN</a>) shares are dropping over 16% this morning.</li>



<li>Mercurity Fintech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfh-stock-quote/">MFH</a>) stock is slipping more than 13% today.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares close out our pre-market stock movers down over 13%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Ocean Biomedical receives non-compliance notice from Nasdaq

Ocean Biomedical (OCEA) just unveiled an update. Ocean Biomedical has been notified by Nasdaq of non-compliance due to its failure to file the mand...

Ocean Biomedical Faces Nasdaq Compliance Challenges

Ocean Biomedical (OCEA) announced that it received a letter from Nasdaq stating that on April 18, May 22 and August 19, staff notified the company ...

Ocean Biomedical receives noncompliance letter from Nasdaq

Ocean Biomedical receives Nasdaq's delisting letter

BWAQ

CHSN

CLNN

GDHG

KITT

MICS

MOLN

OBLG

OCEA

SIFYR

SOUN

SRFM

THMO

TNXP

TSLA

UBXG

VKTX

WLGS

Press Releases

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Comments

Ocean Biomedical

Notizie

Ultime notizie per Ocean Biomedical (NASDAQ:OCEA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO